8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  June 1, 2012
PartnerRe Ltd.
(Exact Name of Registrant as Specified in Charter)
	Bermuda
	(State or Other Jurisdiction of Incorporation)
001-14536		Not Applicable
(Commission File Number)		(IRS Employer Identification No.)
Wellesley House, 90 Pitts Bay Road, Pembroke, Bermuda		HM 08
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s telephone number, including area code: (441) 292-0888

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d)        On June 1, 2012, the Board of Directors of PartnerRe Ltd. (the “Company”) announced that it had appointed Dr. Egbert Willam to fill a vacancy on the Board, effective June 1, 2012. The Board appointed Dr. Willam as a Class III director. Accordingly, his term will expire at the 2014 Annual General Meeting of Shareholders. Dr. Willam will also serve as a member of the Board’s Audit Committee and Nominating & Governance Committee.

Dr. Willam will be compensated on the same terms as the Company’s other non-management directors as described under “Director Compensation” in the Company’s Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 4, 2012, including pursuant to the Amended and Restated Non-Employee Directors Share Plan, which was approved by the Company’s shareholders at its Annual General Meeting on May 16, 2012. In addition, Dr. Willam will enter into an indemnification agreement with the Company in the same form as the Company has entered into such agreements with the other current directors. The form of indemnification agreement was described in, and attached as an exhibit to, the Company’s Form 10-Q filed with the SEC on November 4, 2009.

There is no arrangement or understanding between Dr. Willam and any other persons pursuant to which he was appointed as a director of the Company. There are no transactions in which Dr. Willam has an interest requiring disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing Dr. Willam’s appointment as a director of the Company is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01                      Financial Statements and Exhibits

(d)        Exhibits.

Exhibit No.	Description
99.1	Press Release of PartnerRe Ltd., dated June 1, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PartnerRe Ltd. (Registrant)
Date:	June 1, 2012	By:	/s/ Marc Wetherhill
			Name:	Marc Wetherhill
			Title:	General Counsel

 Index to Exhibits

Exhibit No.	Description
99.1	Press Release of PartnerRe Ltd., dated June 1, 2012

EX-99.1

News Release	PartnerRe

Dr. Egbert Willam Appointed to PartnerRe’s Board of Directors

PEMBROKE, Bermuda, June 1, 2012 -- PartnerRe Ltd. (NYSE, Euronext: PRE) today announced that Dr. Egbert Willam has been appointed to fill a vacancy on its Board of Directors effective June 1, 2012.

Dr. Willam, aged 63 years old, is Founder and President of KEN Investments, a private equity company with a focus on investments and M&A activities in the financial services industry with a concentration in Asia, Latin America and Central and Eastern Europe.

During his 38-year career, he has held senior positions in Munich Re and latterly in Cologne Re where he was manager for their Asia region and established and managed their Tokyo office. In 1990, he was appointed Member of the Executive Board of Cologne Re where he led the transition of the group into “General Cologne Re” – now known as Gen Re.

Dr. Willam currently sits on several Advisory and Supervisory Boards of a number of companies including CICSA Reaseguros S.A., an insurance broker in Panama, and Humanitas AG, a life sciences company. He has also been involved in the foundation of numerous start-ups.

Dr. Willam replaces Jürgen Zech, who retired from PartnerRe’s Board on May 16, 2012 in compliance with its policy requiring retirement at the age of 73. Dr. Willam will serve on PartnerRe Ltd’s Audit and Nominating and Governance Committees.

Commenting on the appointment PartnerRe Chairman Jean-Paul Montupet said, “The Board, Costas Miranthis and I are delighted to have Egbert join PartnerRe’s Board of Directors. His wealth of experience in the reinsurance industry as well as his broader international experience in the financial services industry will be invaluable as PartnerRe looks to further build on its solid track record. We look forward to Egbert’s many contributions.”

PartnerRe Ltd. is a leading global reinsurer, providing multi-line reinsurance to insurance companies. The Company, through its wholly owned subsidiaries, also offers capital markets products that include weather and credit protection to financial, industrial and service companies. Risks reinsured include property, casualty, motor, agriculture, aviation/space, catastrophe, credit/surety, engineering, energy, marine,

PartnerRe Ltd. 90  Pitts Bay Road Pembroke, Bermuda HM 08 Telephone +1 441 292 0888 Fax +1 441 292 6080

2

specialty property, specialty casualty, multiline and other lines, mortality, longevity and health, and alternative risk products. For the year ended December 31, 2011, total revenues were $5.4 billion. At March 31, 2012, total assets were $23.8 billion, total capital was $7.6 billion and total shareholders’ equity was $6.8 billion.

Contacts:

PartnerRe Ltd.

(441) 292-0888

Investor Contact: Robin Sidders, Investor Relations

Media Contact: Celia Powell, Corporate Relations

Sard Verbinnen

(212) 687-8080

Drew Brown/Brianna Kelly